Focus on Survival Over All
Hematologist-oncologist and MPN expert Dr Koprivnikar walks through a hypothetical patient case and shares why her treatment goals for intermediate- or high-risk MF remain the same, whether anemia is present or not.
For US Healthcare Professionals Only
Hematologist-oncologist and MPN expert Dr Koprivnikar walks through a hypothetical patient case and shares why her treatment goals for intermediate- or high-risk MF remain the same, whether anemia is present or not.
Hematologist–oncologist and MPN expert Dr Koprivnikar walks through a hypothetical patient case and shares her perspective on assessing patients with intermediate– or high–risk MF for treatment with JAKAFI XR™ (ruxolitinib) at diagnosis.
MF=myelofibrosis; MPN=myeloproliferative neoplasm.
JAKAFI®/JAKAFI XR™ (ruxolitinib) is for treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
JAKAFI/JAKAFI XR is for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
JAKAFI/JAKAFI XR is for treatment of steroid‑refractory acute graft‑versus‑host disease (aGVHD) in adult and pediatric patients 12 years and older.
JAKAFI/JAKAFI XR is for treatment of chronic graft‑versus‑host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Please see Full Prescribing Information for JAKAFI/JAKAFI XR.